Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MGTX Meiragtx Holdings Plc

Market Closed 12-27 16:00:00 EST

6.21

+0.10

+1.64%

盘后6.21

+0.000.00%

16:26 EST

High6.29	Low5.90	Vol241.30K
Open6.20	D1 Closing6.11	Amplitude6.30%
Mkt Cap485.33M	Tradable Cap186.77M	Total Shares78.15M
T/O1.48M	T/O Rate0.80%	Tradable Shares30.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MGTX","market":"US","secType":"STK","nameCN":"Meiragtx Holdings Plc","latestPrice":6.21,"timestamp":1735333200000,"preClose":6.11,"halted":0,"volume":241303,"hourTrading":{"tag":"盘后","latestPrice":6.21,"preClose":6.21,"latestTime":"16:26 EST","volume":3071,"amount":19071.63,"timestamp":1735334795158},"delay":0,"floatShares":30076406,"shares":78153401,"eps":-1.343948,"marketStatus":"Market Closed","change":0.1,"latestTime":"12-27 16:00:00 EST","open":6.2,"high":6.285,"low":5.9,"amount":1479639.8083,"amplitude":0.063011,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.343948,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735549200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1528430400000,"exchange":"NASDAQ","adjPreClose":6.11,"preHourTrading":{"tag":"盘前","latestPrice":7.09,"preClose":6.11,"latestTime":"07:19 EST","volume":1,"amount":7.09,"timestamp":1735301987428},"postHourTrading":{"tag":"盘后","latestPrice":6.21,"preClose":6.21,"latestTime":"16:26 EST","volume":3071,"amount":19071.63,"timestamp":1735334795158},"volumeRatio":0.5971876843907818,"impliedVol":3.3334,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/MGTX","defaultTab":"news","newsList":[{"id":"2495300298","title":"MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2495300298","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495300298?lang=en_us&edition=fundamental","pubTime":"2024-12-29 19:19","pubTimestamp":1735471162,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now.In this article, we are going to take a look at where MeiraGTx Holdings plc stands against the other gene therapy stocks.As per IMARC, healthcare infrastructure in the US adapted to accommodate gene therapies. As per IQVIA’s tally, 114 gene therapy trials were initiated in the year 2023. Out of this, a large majority  were sponsored by the healthcare industry. As per Kella Kapnisi, Head of Cell and Gene Therapy at Team Consulting , as of now, there are38 cell and gene therapies approved by the FDA. Notably, many of these have reached commercialization through mostly manual laboratory manufacturing processes.As per IMARC, the collaborations between biotech companies, pharmaceutical firms, and university research institutes can pool the funds needed to address challenges related to creating and promoting gene treatments.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-holdings-plc-mgtx-gene-111922323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","PSQ","USJW.SI","MGTX","TQQQ","NQmain","BK4139","MNQmain","SQQQ","QLD","NVIW.SI","USAW.SI","TSYW.SI",".IXIC"],"gpt_icon":1},{"id":"2490452650","title":"MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1","url":"https://stock-news.laohu8.com/highlight/detail?id=2490452650","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490452650?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:38","pubTimestamp":1733841537,"startTime":"0","endTime":"0","summary":"MeiraGTx  announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia, RIX. “This RMAT designation underscores the strength of our data indicating the potential of our AAV2-hAQP1 therapy to significantly improve the lives of patients who suffer from xerostomia following radiation treatment. The requirements for receiving an RMAT designation include that the drug candidate is an advanced regenerative medicine, in this case a gene therapy; that the therapy is targeting a serious condition, in this case, Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract; and that the applicant has presented preliminary clinical evidence demonstrating that the drug candidate has the potential to address an unmet need in the serious condition,” said Alexandria Forbes, Ph.D., president and chief executive officer o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/meiragtx-granted-rmat-designation-u-143857950.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-granted-rmat-designation-u-143857950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MGTX"],"gpt_icon":0},{"id":"2490677991","title":"MeiraGTx's Xerostomia Drug Gets FDA Regenerative Medicine Advanced Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490677991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490677991?lang=en_us&edition=fundamental","pubTime":"2024-12-09 23:13","pubTimestamp":1733757191,"startTime":"0","endTime":"0","summary":"MeiraGTx (MGTX) said Monday that AAV2-hAQP1 received regenerative medicine advanced therapy designation from the US Food and Drug Administration.AAV2-hAQP1 is being developed for the treatment of grad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6522","IE00B19Z4B17.USD","BK4139","IE00B66KJ199.SGD","IE0031619046.USD","BLZ.SI","BK4157","IE00B7SZL793.SGD","AEIS","BK6088","MGTX"],"gpt_icon":0},{"id":"2490245667","title":"MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Aav2-Haqp1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia","url":"https://stock-news.laohu8.com/highlight/detail?id=2490245667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490245667?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA1NJ3YX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MGTX","BK4139"],"gpt_icon":0},{"id":"2486743102","title":"Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2486743102","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486743102?lang=en_us&edition=fundamental","pubTime":"2024-11-25 08:27","pubTimestamp":1732494420,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024.\"I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors,\" said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. \"Both Ms. Bozilenko and Dr. Yu are accomplished industry veterans possessing a wealth of experience in the finance, investment, business development, and strategic management in the global biopharmaceutical sector. Ascentage Pharma is currently at a crucial stage of its development where we are making further strides with our global innovation strategy. W","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","LU0225771236.USD","LU1720051017.SGD","LU1894683348.USD","BK4585","LU0868494617.USD","LU1066051498.USD","LU2271345857.HKD","06855","LU1057294990.SGD","LU0306806265.USD","LU2089284900.SGD","LIAN","BK4568","SG9999001176.SGD","LU1363072403.SGD","PSQ","LU1023059063.AUD","LU2357305700.SGD","LU0098860793.USD","BK4550","SQQQ","BK4581","MNQmain","IE00BLSP4239.USD","NQmain","LU1989772840.SGD","BK4533","LU0456855351.SGD","LU0006306889.USD","IE000M9KFDE8.USD","TQQQ","QID",".IXIC","QLD","LU1720051108.HKD","MGTX","LU0170899867.USD","BK4592","BK1574","OLMA","CDE","IE00B19Z3581.USD","BK4534","TLPH","LU1548497426.USD","BK4017"],"gpt_icon":1},{"id":"2483373601","title":"MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2483373601","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483373601?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:36","pubTimestamp":1731674164,"startTime":"0","endTime":"0","summary":"Shareholders might have noticed that MeiraGTx Holdings plc  filed its quarterly result this time last week. The early response was not positive, with shares down 4.0% to US$6.64 in the past week. Revenues of US$11m crushed expectations, although expenses understandably increased with statutory losses reaching US$0.55 per share, somewhat higher than what the analysts forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.NasdaqGS:MGTX Earnings and Revenue Growth November 15th 2024. With that in mind, we wouldn't be too quick to come to a conclusion on MeiraGTx Hol","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-holdings-plc-nasdaq-mgtx-123604347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","NDAQ","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","BK4112","PSQ","SQQQ","MNQmain","BK4139","NQmain","LU2210149790.SGD","IE00B64PRP62.GBP","TQQQ","QID","IE00BGHQF748.EUR","QLD",".IXIC","MGTX"],"gpt_icon":1},{"id":"2483859384","title":"MeiraGTx Holdings Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2483859384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483859384?lang=en_us&edition=fundamental","pubTime":"2024-11-15 01:11","pubTimestamp":1731604260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MGTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 12:11 ET (17:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX"],"gpt_icon":0},{"id":"2483871665","title":"RBC Raises Price Target on MeiraGTx Holdings to $11 From $9, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2483871665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483871665?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:23","pubTimestamp":1731587010,"startTime":"0","endTime":"0","summary":"RBC Raises Price Target on MeiraGTx Holdings to $11 From $9, Keeps Outperform, Speculative Risk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MGTX"],"gpt_icon":0},{"id":"2483886358","title":"MeiraGTx Holdings PLC reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483886358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483886358?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:14","pubTimestamp":1731507296,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings PLC reports results for the quarter ended September 30 - Earnings SummaryMeiraGTx Holdings PLC MGTX.OQ reported a quarterly adjusted loss of 55 cents per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK1GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX"],"gpt_icon":0},{"id":"2483007523","title":"MeiraGTx Hldgs Q3 2024 GAAP EPS $(0.55) Misses $(0.53) Estimate, Sales $10.90M Beat $1.63M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007523","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007523?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:13","pubTimestamp":1731503636,"startTime":"0","endTime":"0","summary":"MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.53) by 3.77 percent.  The company reported quarterly sales of $10.90 million which beat the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41937653/meiragtx-hldgs-q3-2024-gaap-eps-0-55-misses-0-53-estimate-sales-10-90m-beat-1-63m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MeiraGTx Hldgs Q3 2024 GAAP EPS $(0.55) Misses $(0.53) Estimate, Sales $10.90M Beat $1.63M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX"],"gpt_icon":0},{"id":"2482484774","title":"MeiraGTx Holdings PLC  expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482484774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482484774?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:54","pubTimestamp":1731084845,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings PLC  expected to post a loss of52cents a share - Earnings Preview MeiraGTx Holdings PLC MGTX.OQ MGTX.O is expected to show a fall in quarterly revenue when it reports  results on Nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF2XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYC","MGTX"],"gpt_icon":0},{"id":"2477336996","title":"MeiraGTx announecs five posters at ESGCT 2024 Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2477336996","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477336996?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:31","pubTimestamp":1729600273,"startTime":"0","endTime":"0","summary":"MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, whic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/meiragtx-announecs-five-posters-at-esgct-2024-annual-congress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/meiragtx-announecs-five-posters-at-esgct-2024-annual-congress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MGTX"],"gpt_icon":0},{"id":"2477380883","title":"MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (Esgct) 2024 Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2477380883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477380883?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUA6GDSM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MGTX"],"gpt_icon":0},{"id":"2477435335","title":"MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2477435335","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477435335?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598400,"startTime":"0","endTime":"0","summary":"Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms. LONDONandNEW YORK, Oct. 22, 2024  -- MeiraGTx Holdings plc , a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy  2024 Annual Congress, which is being held from October 22-25, 2024, in Rome, Italy.The posters are available on the Posters and Publications page of the Company’s website.The details of the poster presentations are as follows:","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8wKC2FWfAsb3K9HApbTCpQ--~B/aD04MDt3PTQwNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7d3a2fa2ab3c203b44f402dd7f69c584","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8wKC2FWfAsb3K9HApbTCpQ--~B/aD04MDt3PTQwNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7d3a2fa2ab3c203b44f402dd7f69c584"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-announces-five-posters-european-120000990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MGTX","BK4139"],"gpt_icon":0},{"id":"2477662268","title":"High Growth Tech Stocks to Watch in October 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2477662268","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477662268?lang=en_us&edition=fundamental","pubTime":"2024-10-21 22:02","pubTimestamp":1729519364,"startTime":"0","endTime":"0","summary":"The United States market has remained flat over the last week but is up 38% over the past year with earnings expected to grow by 15% annually. In this context, high growth tech stocks that exhibit robust innovation and scalability potential are particularly noteworthy as they can capitalize on these favorable economic conditions.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.Operations: The company generates revenue primarily through its advertising segment, which amounted to $1.62 billion. Operating across multiple countries, it leverages an AI-driven platform to deliver targeted ad solutions.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jtwePbKEAZvFHrncXoq7iQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jtwePbKEAZvFHrncXoq7iQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-140244903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4157","MGTX","TBLAW","CXT","TBLA","BK4161"],"gpt_icon":0},{"id":"2476945028","title":"MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2476945028","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476945028?lang=en_us&edition=fundamental","pubTime":"2024-10-16 22:19","pubTimestamp":1729088340,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease  metits primary study objective of safetyand tolerability. The stock soared 14.9% in response to the news.MGTX’s PD Gene Therapy Candidate Betters Sham Treatment. The MGT-GAD-025 study of AAV-GAD for PD demonstrated significant and clinically meaningful improvements from baseline for key efficacy endpoints after 26 weeks of treatment.The investigational gene therapy was also found to be generally safe and overall well-tolerated. No serious, AAV-GAD treatment-related adverse events wereobserved.AAV-GAD has a novel mechanism of action that aims to correct the aberrant circuitry that results from the depletion of dopamine in the brain of idiopathic PD patients as the disease progresses. Using the company's proprietary delivery instrument, AAV-GAD is administered as a one-time infusion into the subthalamic nucleus, a key regulator of the circuits responsible for normal m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/x7AJ0AkRL_CYuqXFyPb2BQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mgtx-stock-upbeat-efficacy-data-141900975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065169927.USD","BK4588","LU1169589451.USD","LU2065170008.USD","LU2065171402.SGD","FOLD","PD","BK4023","ALNY","BK4139","MGTX","BK4007","BK4548","LU2065171311.SGD","BK4585","ANIP","LU1169590202.USD"],"gpt_icon":0},{"id":"2475296276","title":"MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2475296276","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475296276?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:30","pubTimestamp":1729078215,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Meiragtx Holdings .MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s disease, showcasing significant improvements in both motor function and quality of life. The study demonstrated an 18-point average improvement in motor scores for the high dose group and noted meaningful enhancements in patient-reported outcomes, with no serious adverse events reported. This progress paves the way for a potential Phase 3 trial, aiming to position AAV-GAD as a groundbreaking treatment for Parkinson’s globally.For a thorough assessment of MGTX stock, go to TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qPv1d3QqkuUgAPFZhs.xQg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/77a747ee2b92f942aa044f4f47d9af54","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qPv1d3QqkuUgAPFZhs.xQg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/77a747ee2b92f942aa044f4f47d9af54"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/meiragtx-holdings-reports-promising-parkinson-113015660.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-holdings-reports-promising-parkinson-113015660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MGTX","BK4139"],"gpt_icon":0},{"id":"2475910246","title":"MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2475910246","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475910246?lang=en_us&edition=fundamental","pubTime":"2024-10-16 18:45","pubTimestamp":1729075500,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings PLC  shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks.The stock price rally was observed after the company reported positive topline data from itsclinical bridging study of AAV-GAD for treating Parkinson’s disease . Per the data readout, it was observed that treatment with the investigational gene therapy resulted in superior efficacy over sham treatment in PD patients, at week 26. The candidate was also safe and overall well-tolerated. Based on the encouraging data readout from the study, MeiraGTx is currently gearing up to discuss these results with regulatory bodies in the United States, E.U. and Japan to potentially initiate a phase III study that will support the approval of this disease-modifying treatment globally.This company is expected to post quarterly loss of $0.47 per ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F3SzLjvem9FxnCfOUlLFvw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0abdcee17aba3223065f252e14650089","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F3SzLjvem9FxnCfOUlLFvw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0abdcee17aba3223065f252e14650089"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meiragtx-mgtx-surges-14-9-104500344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0889565916.HKD","LU1169589451.USD","MRUS","LU1169590202.USD","LU0109394709.USD","BK4023","MGTX","PD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2475659415","title":"MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2475659415","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475659415?lang=en_us&edition=fundamental","pubTime":"2024-10-16 01:32","pubTimestamp":1729013526,"startTime":"0","endTime":"0","summary":"MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores.The company plans to discuss phase 3","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1585548490/image_1585548490.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1585548490/image_1585548490.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4726921-meiragtx-positive-pd-data-moves-needle-forward-for-regulatory-meetings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","MGTX"],"gpt_icon":0},{"id":"2475637339","title":"Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2475637339","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475637339?lang=en_us&edition=fundamental","pubTime":"2024-10-16 00:13","pubTimestamp":1729008793,"startTime":"0","endTime":"0","summary":"On Tuesday, MeiraGTx Holdings plc released topline data from its clinical bridging study of AAV-GAD for Parkinson’s disease, MGT-GAD-025.MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform process.Participants had idiopathic Parkinson’s disease, a history of levodopa responsiveness for at least 12 months, and a UPDRS Part 3 score of ≥25 points in the “off” state.Fourteen subjects were randomized to one of three groups . The primary objective of the study was to evaluate the safety and tolerability of AAV-GAD, with exploratory efficacy endpoints including the mean change from baseline to Week 26 in MDS-UPDRS Part 3  scores in the “off” state and the Parkinson’s Disease Questionnaire  score, a key patient-reported quality of life measure in Parkinson’s disease.AAV-GAD was safe and well tolerated, with no serious adverse events  related to AAV-GA","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/eAhdl2vJEJUWn40MDByz1A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c482c1a64cd7abad96253c1628a282f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/eAhdl2vJEJUWn40MDByz1A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c482c1a64cd7abad96253c1628a282f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-meiragtx-reveals-encouraging-161313648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MGTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.meiragtx.com","stockEarnings":[{"period":"1week","weight":0.0098},{"period":"1month","weight":-0.0519},{"period":"3month","weight":0.4577},{"period":"6month","weight":0.4751},{"period":"1year","weight":-0.1278},{"period":"ytd","weight":-0.1154}],"compareEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":-0.0064},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.0933},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.2518}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014395},{"month":2,"riseRate":0.5,"avgChangeRate":0.023237},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.086393},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.037019},{"month":5,"riseRate":0.666667,"avgChangeRate":0.038447},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.012146},{"month":7,"riseRate":0.571429,"avgChangeRate":0.004446},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.045465},{"month":9,"riseRate":0.714286,"avgChangeRate":-0.022043},{"month":10,"riseRate":0.285714,"avgChangeRate":0.085483},{"month":11,"riseRate":0.714286,"avgChangeRate":0.070882},{"month":12,"riseRate":0.714286,"avgChangeRate":0.069717}],"exchange":"NASDAQ","name":"Meiragtx Holdings Plc","nameEN":"Meiragtx Holdings Plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Meiragtx Holdings Plc,MGTX,Meiragtx Holdings Plc股票,Meiragtx Holdings Plc股票老虎,Meiragtx Holdings Plc股票老虎国际,Meiragtx Holdings Plc行情,Meiragtx Holdings Plc股票行情,Meiragtx Holdings Plc股价,Meiragtx Holdings Plc股市,Meiragtx Holdings Plc股票价格,Meiragtx Holdings Plc股票交易,Meiragtx Holdings Plc股票购买,Meiragtx Holdings Plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Meiragtx Holdings Plc(MGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Meiragtx Holdings Plc(MGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction